Über den Autor
K. Izuhara, MD, PhD, Saga Medical School, Nabeshima, Japan
Stephen T. Holgate, MD, DSc, FRCP, Southampton General Hospital, UK
Marsha Wills-Karp, PhD, Children's Hospital Medical Center, Cincinnati, USA
Contributors, viirnPreface, xiiirnPart I: Cells contributing to the pathogenesis of allergic diseases in the respiratory tractrn1 Novel anti-infl ammatory drugs based on targeting lung dendritic cells and airway epithelial cells, 3nBart N. Lambrecht, Maud Plantinga, Monique Willart, and Hamida Hammadrn2 Role of Th2 cells in the allergic diathesis, 15nMarsha Wills-Karprn3 Importance of Th17- and Th1-associated responses for the development of asthma, 27nTomohiro Yoshimoto, Hiroko Tsutsui, and Kenji Nakanishirn4 Regulatory T cells, 39nChris Corrigan and Kimuli Ryannarn5 A role for natural killer T-cell subsets in the pathogenesis of various allergic disorders, 59nHiroshi Watarai, Michishige Harada, Mayumi Tamari, and Masaru Taniguchirn6 Regulatory roles of B cells in allergy and infl ammation, 67nKiyoshi Takatsu, Masashi Ikutani and Yoshinori Nagairn7 Mast cells, 79nMindy Tsai and Stephen J. Gallirn8 Eosinophils, 107nNancy A. Lee, Mark V. Dahl, Elizabeth A. Jacobsen, and Sergei I. Ochkurrn9 Basophils in infl ammation and allergy drug design, 123nDonald MacGlashan, Jr.rn10 Epithelial cells, 139nTillie-Louise Hackett, Stephanie Warner, Dorota Stefanowicz, and Darryl Knightrn11 Fibroblasts, 149nAlastair G. Stewart, Lilian Soon, and Michael Schuligarn12 Airway smooth muscle cells, 163nAndrew J. Halayko and Pawan SharmarnPart II: Cytokines contributing to the pathogenesis of allergic diseases in the respiratory tractrn13 Interleukin 4, interleukin 13, and interleukin 9, 175nKenji Izuhara, Shoichiro Ohta, Hiroshi Shiraishi, and Shoichi Suzukirn14 Interleukin 3, interleukin 5, and granulocyte-macrophage colony-stimulating factor, 187nAlba Llop-Guevara, Josip Marcinko, Ramzi Fattouh, and Manel Jordanarn15 Interleukin 15, interleukin 17, and interleukin 25, 197nHiroshi Nakajima and Itsuo Iwamotorn16 Thymic stromal lymphopoietin, 205nKazuhiko Arima and Yong-Jun Liurn17 Interleukin 10, 215nWhitney W. Stevens, Larry Borish, and John W. Steinkern18 Tumor necrosis factor alpha, 225nChristopher Brightling, Latifa Chachi, Dhan Desai, and Yassine Amranirn19 Profi brotic and angiogenic factors in asthma, 237nNeville Berkman and Francesca Levi-Schafferrn20 Chemokines, 253nLuis M. Teran and Juan R. Velazquezrn21 Epithelial growth factors, 263nYasuhiro Gon and Shu HashimotornPart III: Other mediators contributing to the pathogenesis of allergic diseases in the respiratory tractrn22 Prostanoids, 273nSarah A. Maher, Deborah L. Clarke, and Maria G. Belvisirn23 Leukotrienes, 285nKatsuhide Okunishi and Marc Peters-Goldenrn24 Proteases in allergy, 297nKeisuke Oboki and Hirohisa Saitorn25 Toll-like receptors, 307nJessica L. Allen, Aurelien Trompette, and Christopher L. KarprnIndex, 317
Our knowledge and understanding of allergic diseases of the respiratory tract has improved to a point where new therapies are being developed for patient benefit.rnInflammation and Allergy Drug Design explains the biologic science that underpins the pathophysiology of asthma and related disorders, as well as their mechanisms. This authoritative guide consists of 25 chapters, each detailing the cutting-edge developments in a particular field. It is divided into three parts, covering cytokines, chemokines, grow factors and mediators.rnThis book allows immunologists, allergologists and researchers in the pharmaceutical industry to learn and appreciate the target biology in drug development. It also provides medical and pharmaceutical postgraduatenstudents and clinicians with a basic understanding of allergic diseases in the respiratory tract.